✦ LIBER ✦

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

✍ Scribed by Fausto Petrelli, Karen Borgonovo, Veronica Lonati, Stefano Elia…

Book ID: 120837915
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 255 KB
Volume: 8
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-012-0240-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5001 ORAL Intraperitoneal administration

5001 ORAL Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study

✍ Parsons, S.; Kutarska, E.; Koralewski, P.; Gore, M.; Wimberger, P.; Burges, A.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Catumaxomab with and without prednisolon

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

✍ Jalid Sehouli,Klaus Pietzner,Pauline Wimberger,Ignace Vergote… 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 328 KB

The trifunctional antibody catumaxomab f

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

✍ Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 559 KB

## Abstract Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascite